BELLEVUE, Wash., May 23, 2014 (GLOBE NEWSWIRE) -- VitaCig, Inc. and mCig, Inc. (Stock Symbol:MCIG) Company welcomes the release of the results of University College London's five-year survey of nearly 6,000 smokers in England. According to the study's results, which were published in the journal Addiction, respondents attempting to quit smoking without professional help had an odds of success approximately 60% higher if they used e-cigarettes than if they used willpower alone or over-the-counter nicotine replacement therapies such as patches or gum.

In a press release announcing the study's findings, the authors also note that, in England, smoking rates are declining, quitting rates are increasing, and regular e-cigarette use among newer smokers is negligible. The same release also notes that, while the authors track the issue "very closely," they have seen no evidence that electronic cigarettes could "re-normalize smoking."

To read the report in its entirety visit: http://onlinelibrary.wiley.com/doi/10.1111/add.12623/abstract

VitaCig, Inc. which has developed a $2 vitamin-infused, nicotine-free alternative to traditional e-cigarettes believes the results of this study are helpful in addressing some of the recent concerns surrounding the electronic cigarette industry from the anti-smoking lobby.

"The idea that, inhaling vapor from a device resembling a traditional cigarette, is somehow the same as inhaling tar, tobacco, smoke, or carcinogens is scientifically incorrect. Vapor, is chemically identical to steam while smoke, is the byproduct of combustion. With VitaCig, we have supplemented nicotine with vitamins and smoke with vapor while providing the same hand-to-mouth activity that is in our view, at the heart of the traditional smoking experience. We hope that the study published yesterday will help shape the conversation going forward and re-introduce the merits of this innovative technology. Industry watchers should keep in mind that global e-cigarette adoption has occurred at a faster rate than mobile phone adoption. In my personal view, this would not have transpired unless e-cigarettes were providing a utility for traditional smokers in their pursuit of harm-reduction." Said Paul Rosenberg, CEO of mCig, Inc.

About VitaCig, Inc.

VitaCig, Inc. is a technology company that is harnessing mobile vaporization technology for medical delivery applications. The company has launched its first consumer product: The VitaCig, a $2 nicotine-free device that looks and feels like an electronic cigarette (eCig). Unlike a traditional eCig, the VitaCig delivers a vapor of natural flavors, vitamins, and phytonutrients. Initially the VitaCig will be produced in three flavor categories: Relax, Refresh, Energize with plans for additional flavor categories and targeted medical applications in the future. The company is currently a subsidiary of mCig, Inc. (Stock Symbol:MCIG) that is in the process of being spun-off to shareholders in 2014.

The traditional tobacco industry is estimated at nearly $900 Billion a year. Financial analysts from Wells Fargo, Goldman Sachs, and Citigroup predict that by 2022 Electronic Cigarettes will supplant the traditional tobacco industry and eventually grow into a $1 Trillion industry.

VitaCig is disrupting both the traditional tobacco industry and the growing electronic cigarette industry by appealing to the existing 1.2 Billion adults globally that smoke cigarettes, providing them with a nicotine and tobacco-free alternative that may assist in harm reduction. Moreover, the company is expanding the target market beyond the 1.2 Billion adults by appealing to non-smokers or occasional smokers with a superior method for the consumption of Vitamins, Nutrients, and other compounds with medicinal efficacy. – To learn more visit: http://www.vitacig.org/investors/investor-opportunity-subpage/

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.